Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 94

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 94
---
.00 per Ordinary Share, which is the midpoint of the price range set forth on
the cover page of this prospectus, would increase (decrease), the net proceeds to us from this offering by $0.27 million, assuming the
number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of Ordinary Shares
we are offering. An increase (decrease) of 100,000 in the number of Ordinary Shares offered by us would increase (decrease)
the net proceeds to us from this offering by $1.07 million, assuming no change in the assumed initial public offering price and after
deducting underwriting discounts and commissions and estimated offering expenses payable by us.

We currently expect to use
the net proceeds from this offering for the following purposes:

| ● | approximately $4.5 million for development activities (including                        
 the completion of our pivotal trial) and preparation of the PMA submission for GelrinC; |

| ● | approximately $1.0 million for operations (manufacturing, regulatory 
 affairs and patents);                                                |

| ● | approximately $0.5 million for research and development activities; |

| ● | approximately $0.5 million                                                          
 for EU marketing development (Medical Device Regulation qualification and scaleup); |

| ● | approximately $0.8 million for the repayment of the Bridge Loan,                                                                 
 the 2024 Loan Agreements and the December 2024 Loan (as defined below) and the applicable accrued interest and risk premium; and |

| ● | the remainder for working                                                
 capital and general corporate purposes and possible future acquisitions. |

Although we currently anticipate
that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is
necessary. Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate
with certainty the exact amounts of the net proceeds from this offering that may be used for any of the above purposes on a stand-alone
basis. Amounts and timing of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization
efforts, regulatory approval and demand for our product candidates, operating costs and other factors described under “Risk Factors”
in this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this